Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Psychopharmacology (Berl). 2019 Mar 27;236(9):2635–2640. doi: 10.1007/s00213-019-05235-x

Table 3.

Behavioral Outcomes

Mean (SD)
Outcome Haloperidol Placebo
−90 −30 +15 +65 +140 +190 −90 −30 +15 +65 +140 +190
PANSS Positive 7.78(1.09) 7.89(1.16) 7.78(1.09) 7.78(1.09) 9(1.5) 7.56(1.13) 7.4(0.52) 7.4(0.52) 7.4(0.5 2) 7.5(0.71) 10.3(0.95) 7.8(0.91)
Negative 6.78(1.3) 6.44(1.01) 6.22(0.44) 6.33(0.71) 8.63(1.85) 6.4(0.72) 6.4(0.7) 6.2(0.42) 6.1(0.31) 6.2(0.42) 7.7(1.16) 6.3(0.67)
General Psychopath ology 15.67(1) 15.67(0.87) 16(0.71) 15.56(0.73) 18.11(1.69) 15.67(0.71) 15.3(0.48) 15.5(0.71) 15.6(0.7) 15.5(0.85) 18.9(3.03) 15.6(0.7)
Total 30.22(2.91) 30(2.29) 30(1.58) 29.67(1.32) 35.88(2.52) 29.67(2) 29.1(1.1) 29.1(0.99) 29.1(0.88) 29.2(1.03) 36.9(3.51) 29.7(1.42)
CADSS Clinician rated 0 0 0.22(0.66) 0 3.33(0.22) 0.125(0.1) 0(0) 0.1(0.33) 0.1(0.32) 0.1(0.32) 4.7(2.6) 0.4(0.7)
Subjective 0.22(0.67) 0.5(1.67) 0.67(1) 0.2(0.67) 3.7(3.15) 1(2.12) 0.1(0.31) 0.2(0.42) 0(0) 0.2(0.63) 6.7(5.05) 1.9(2.4)

PANSS: Positive and Negative Syndrome Scale. CADSS: Clinician-Administered Dissociative States Scale.